Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telomir Pharmaceuticals, Inc. ( (TELO) ) has issued an announcement.
On February 5, 2026, Telomir Pharmaceuticals reported preclinical cellular data showing that its lead compound Telomir-1, in the Telomir-Zn formulation, rapidly and dose-dependently increases intracellular zinc while reducing labile ferrous iron without harming cell viability, suggesting a coordinated metal-exchange mechanism that may mitigate oxidative stress and stabilize mitochondrial, genomic, and epigenetic functions linked to both cancer and age-related cellular decline. The company indicated that these findings support a foundational epigenetic modulation mechanism rather than a cytotoxic approach, as it progresses a broader portfolio of preclinical programs in triple-negative breast cancer and longevity models, prepares manuscripts for peer-reviewed publication, and moves toward filing an Investigational New Drug application in the first quarter of 2026, underscoring its push to translate this mechanistic platform into clinical development.
The most recent analyst rating on (TELO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a drug development company focused on epigenetic and cellular mechanisms implicated in cancer and aging, advancing a pipeline centered on its lead investigational compound Telomir-1, including its Telomir-Zn formulation, through preclinical programs in oncology and longevity.
Average Trading Volume: 351,582
Technical Sentiment Signal: Sell
Current Market Cap: $39.88M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.